Top Tweets for #cotadutide
🌍 The global surge in cardiometabolic diseases—#T2D, #obesity, #CVD—is demanding more than incremental solutions.
Dual GLP-1/glucagon receptor agonists (e.g., #survodutide, #cotadutide) are reshaping the therapeutic landscape:
✅ Superior glucose control (HbA1c↓)
✅ Enhanced weight loss
✅ Increased energy expenditure & fat oxidation
✅ Reduction in liver fat (MASLD)
✅ Promising CV & renal outcomes
🔍 This review highlights the transformative potential of dual GLP-1/Gcg receptor agonists, providing a thorough examination of their mechanisms of action, clinical efficacy, and safety profiles across the cardio–metabolic continuum.
✒️ Author: Panagiotis Stachteas, @nasoufidou_athi , Paschalis Karakasis, Markella Koiliari, Efstratios Karagiannidis, Theocharis Koufakis, Nikolaos Fragakis, @DPatoulias
🏪 Affiliation: @Auth_University Aristotle University of Thessaloniki
🔔 Full Text: https://t.co/Os9lAnKShp
#Diabetes #Obesity #GLP1 #MASLD #CardioRenal #PrecisionMedicine #PharmaInnovation
1)#Tirzepatide coagoniza con un ratio 5:1 al receptor GIP (GIPr)...versus al receptor GLP1 (GLP1r).
2)#Cotadutide coagoniza con un ratio 5:1 al GLP1r versus al receptor del glucagón (GCr).
3)#Survodutide coagoniza de manera similar al previo, ratio 5:1 al GLP1r versus al GCr.
OBESITY
📌Not just⬇️weight but FAT REDISTRIBUTION
⚠️Careful balance DIET-EXERCISE not to worsen obesity-related-sarcopenia
✅BIMAGRUMAB keeps advancing in the development of new therapies for cardio-kidney-hepato-gut-muscle-metabolic dysfunction
#cotadutide #CVVT24 #retatutide
Our work on dual GLP-1 & glucagon receptor agonism with #cotadutide and mechanisms of weight loss👇@MEvansCambridge @JaneKennet @albert_koulman @cambridge @IMS_MRL @CambridgeCRF
Dual GLP-1 and Glucagon receptor agonism with #cotadutide produces modest weight loss. Weight change was -4.0% for the cotadutide and -1.4% for the placebo group.
https://t.co/yJRZLdtmX5
Dual GLP-1 and Glucagon receptor agonism with #cotadutide produces modest weight loss. Weight change was -4.0% for the cotadutide and -1.4% for the placebo group.
https://t.co/yJRZLdtmX5
https://t.co/OwdIe0wmT1 MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study #acd2021 #Cotadutide @acdiabetis
The next frontier is #NAFLD. There are other twins out there, e.g. #Cotadutide (#GLP1/#glucagon dual agonist), which demonstrated some promising data vs Liraglutide recently https://t.co/rEAVf4qjdi
#Cotadutide is a dual receptor agonist with #GLP1 activity with greater improvement in liver enzymes for same weight loss compared to #liraglutide - but trade off is more GI side effects (and discontinuation!). Let’s see what the trial specifically for #NAFLD shows #LiverMtg19
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers